TDOC. Tell a repricing finally?Teladoc Health, Inc.BATS:TDOCMRCMM The striking point that seems assymetrical, in this play is Revenue base is massive relative to valuation. Teladoc, generates roughly $2.5 billion of annual revenue, while trading at a market value, that is only a fraction, of what it was during the pandemic. The collapse from peak valuation ,as an overcorrection ,caused by the Livongo acquisition disaster, and subsequent write-downs ,rather than a reflection, of the underlying operating business. BetterHelp not good also, pointing declines to stop within the next 1–2 years. The insurance-covered therapy strategy ,can offset weakness in the traditional cash-pay model. Management has highlighted, rapid growth in insurance-related revenue and better performance, in markets where insurance coverage is available. If BetterHelp merely stops shrinking, sentiment toward the stock could change dramatically. At the current time, TDOC seems a mispriced healthcare infrastructure company. Trading as if its struggling BetterHelp segment, defines the entire business; if BetterHelp stabilizes and Integrated Care, continues generating cash flow, the stock could be worth substantially, more than today's valuation.